ETFIQData as of Nov 19, 2026. · etfiq.com/funds/gnom

GNOM Fact Sheet: Global X Genomics & Biotechnology ETF

Share
$57.08
close, Nov 20, 2026

Over the year to Nov 19, 2026, GNOM returned +39.6% in total and charged 0.50% a year.

1-year total return
+37.2%
to Nov 20, 2026
Expense ratio
0.50%
a year
Net assets
$108m
on Nov 11, 2026
Net flow, 12 months to Aug 31, 2026
+$2.5m
daily basis to Nov 11, 2026

Growth of $10,000, 1 year

GNOM $13,965 +39.6% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.

Returns

WindowTotal return
1 month−16.9%
3 months−14.5%
Year to date+25.7%
1 year+37.2%
3 years+40.6%
5 years−32.5%

Total return, distributions reinvested, each window to Nov 20, 2026.

Ten largest positions

HoldingWeight
MODERNA, INC.7.50%
Twist Bioscience Corporation6.34%
10x Genomics, Inc.5.48%
GUARDANT HEALTH, INC.5.28%
ILLUMINA, INC.4.87%
NATERA, INC.4.61%
Genscript Biotech Corp3.81%
VERTEX PHARMACEUTICALS INCORPORATED3.70%
BIO-TECHNE CORPORATION3.67%
BIOMARIN PHARMACEUTICAL INC.3.58%

GNOM top ten by weight, 48.8% of the fund, of its 50 equity positions, from the holdings filed for Aug 31, 2026.

Facts

Holds 50 stocks in genomics and gene editing, 27% of its weight in S&P 500 companies · First traded Apr 10, 2019 · Benchmark Its own holdings, as of Nov 11, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, GNOM Fact Sheet: Global X Genomics & Biotechnology ETF. Data as of Nov 19, 2026. https://etfiq.com/funds/gnom/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/gnom.